He Qiao, Tuo Yi, Zhou Yi, Yan Yue, Liu Xin, Zhao Dan, Wang Qiuju, Luo Hao, Zhang Zhengyao, Meng Fanping, Ying Binwu, Wang Dongsheng, Yang Mu, Huang Yecai
Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610000, China.
Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, 610000, China.
Sci Rep. 2025 Mar 17;15(1):9186. doi: 10.1038/s41598-025-93406-6.
To compare the performance of magnetic bead (MB) and the concentrated precipitation (CP) based RT-qPCR to qualify cell free EBV DNA (cfEBV DNA) for nasopharyngeal carcinoma (NPC) in non-endemic area of China. From January 2014 to June 2024, a retrospective analysis of 2 cohort studies on cfEBV DNA in NPC patients was conducted to assess the diagnostic value, positive detection rate and clinical application. cfEBV DNA detection with CP based RT-qPCR in cohort 1 and MB based RT-qPCR method in cohort 2. The MB based RT-qPCR for the quantitative measurement of cfEBV DNA load was higher than the CP based RT-qPCR in the same plasma samples from NPC patients (P < 0.001). CP based RT-qPCR measured cfEBV DNA in 1405 NPC and 244 healthy controls in cohort 1 with 40.8% sensitivity (AUC = 0.704, 95% CI: 0.676-0.731). In cohort 2(683 naive NPC and 303 controls), cfEBV DNA had a sensitivity of 75.84% (AUC = 0.879, 95% CI: 0.86-0.90). There were no significant differences in TNM stage among NPC between the two cohorts (P > 0.05). The MB method considerably increased the positive detection rate of cfEBV DNA in NPCs at stages III-IV, T2-T4, N1-N3, and M0 (P < 0.001). At the end of treatment, 97.51% of patients had no detectable EBV and just 2.49% had detectable cfEBV DNA. Those who received ≤ 2 or ≥ 3 cycles of NAC had a median t clearance rate of 9.8 days and 12.6 days, respectively. MB based RT-qPCR increased the quantity of cfEBV DNA. MB based RT-qPCR demonstrated superior sensitivity and positive detection rates for cfEBV DNA. cfEBV DNA can be more positively noticed, with a higher diagnostic value and a broader variety of clinical applications among NPC in non-endemic areas.
为比较基于磁珠(MB)和基于浓缩沉淀(CP)的逆转录定量聚合酶链反应(RT-qPCR)检测中国非流行地区鼻咽癌(NPC)患者游离EB病毒DNA(cfEBV DNA)的性能。2014年1月至2024年6月,对2项关于NPC患者cfEBV DNA的队列研究进行回顾性分析,以评估其诊断价值、阳性检出率及临床应用情况。队列1采用基于CP的RT-qPCR检测cfEBV DNA,队列2采用基于MB的RT-qPCR方法。在来自NPC患者的相同血浆样本中,基于MB的RT-qPCR对cfEBV DNA载量的定量测量高于基于CP的RT-qPCR(P<0.001)。队列1中,基于CP的RT-qPCR检测了1405例NPC患者和244例健康对照,灵敏度为40.8%(曲线下面积[AUC]=0.704,95%置信区间[CI]:0.676-0.731)。在队列2(683例初治NPC患者和303例对照)中,cfEBV DNA的灵敏度为75.84%(AUC=0.879,95%CI:0.86-0.90)。两个队列中NPC患者的TNM分期无显著差异(P>0.05)。MB法显著提高了III-IV期、T2-T4期、N1-N3期和M0期NPC患者cfEBV DNA的阳性检出率(P<0.001)。治疗结束时,97.51%的患者检测不到EB病毒,仅2.49%的患者可检测到cfEBV DNA。接受≤2个或≥3个周期新辅助化疗(NAC)的患者,cfEBV DNA清除率中位数分别为9.8天和12.6天。基于MB的RT-qPCR增加了cfEBV DNA的量。基于MB的RT-qPCR对cfEBV DNA显示出更高的灵敏度和阳性检出率。在非流行地区的NPC患者中,cfEBV DNA能被更积极地检测到,具有更高的诊断价值和更广泛的临床应用。